Evaluation of quinolone derivatives for antitrypanosomal activity

Tropical Medicine and International Health

Volumn 6, Issue 5, 2001, Pages 369-389

  Keiser, J ^a   Burri, C ^a  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

Author keywords

Drug screening; Quinolones; Sleeping sickness; Structure activity relationship; Topoisomerase; Trypanosomes; Trypanosomiasis

Indexed keywords

2 STYRYLQUINAZOLIN 4(3H) ONE DERIVATIVE; 2 STYRYLQUINAZOLINE DERIVATIVE; 5 AMINO 7 (7 AMINO 5 AZASPIRO[2.4]HEPT 5 YL) 1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 8 METHYL 4 OXO 3 QUINOLINECARBOXYLIC ACID; ANTITRYPANOSOMAL AGENT; CIPROFLOXACIN; DIHYDRONICOTINIC ACID DERIVATIVE; DW 271; E 4889; FANDOFLOXACIN; G 59030; G 64070; G 67012; G 71258; G 71286; G 72800; GATIFLOXACIN; GEMIFLOXACIN; MF 5101; MF 5124; MF 5137; MF 5142; MF 5168; MOXIFLOXACIN; NORFLOXACIN; QUINAZOLIN 4(3H) ONE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SITAFLOXACIN; THIAZOLOPYRAZINE DERIVATIVE; UM 35; UM 36; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ARTICLE; CELL STRAIN HT29; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SCREENING; DRUG STRUCTURE; FEMALE; FLUOROMETRY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROTOXICITY; NONHUMAN; STRUCTURE ACTIVITY RELATION; TRYPANOSOMA RHODESIENSE; TRYPANOSOMIASIS;

ANIMALS; ANTI-INFECTIVE AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE; FLUOROQUINOLONES; HUMANS; MICE; MICROBIAL SENSITIVITY TESTS; TRYPANOCIDAL AGENTS; TRYPANOSOMIASIS, AFRICAN;

ANIMALIA; PROTOZOA; TRYPANOSOMA; TRYPANOSOMA BRUCEI RHODESIENSE;

EID: 0034985960     PISSN: 13602276     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3156.2001.00713.x     Document Type: Article

References (25)

1. Cultivation in a semi-defined medium of animal infective forms of Trypanosoma brucei, T. equiperdum, T. evansi, T. rhodesiense and T. gambiense
2. Discontinuous transcription and antigenic variation in trypanosomes
3. Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers
4. Limited activity of bacterial DNA topoisomerase inhibitors against Leishmania donovani and Trypanosoma cruzi amastigotes in vitro
5. Structure-activity and structure-side-effect relationships for the quinolone antibacterials
6. Synthesis and activity of some quinolone derivatives against Plasmodium falciparum in vitro
7. The molecular biology of trypanosomes
8. Mel B in the treatment of human trypanosomiasis
9. Antitumor 2,3-dihydro-2(aryl)-4(1H)-quinazolinone derivatives
10. 50 in studies of drug resistance of malaria parasites
11. An "in vitro selectivity index" for evaluation of cytotoxicity of antitrypanosomal compounds
12. Mechanistic aspects of DNA topoisomerases
13. Antitrypanosomal activity of fluoroquinolones
14. Quinolones in perspective
15. A new fluorometric assays for cytotoxicity measurements in vitro
16. Gambiense trypanosomiasis: Frequency of, and risk factors for, failure of melarsoprol therapy
17. Potent antibacterial fluoroquinolones with marked activity against Leishmania donovani in vivo
18. The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T. b. rhodesiense and T. b. gambiense) in vitro
19. Quinolone therapy for infections of the central nervous system
20. Human African trypanosomiasis: An emerging public health crisis
21. Toxicity of quinolone antimicrobial agents
22. Current sleeping sickness situation and control strategies
23. Molecular mechanisms and therapeutic approaches to the treatment of African trypanosomiasis
24. Control and surveillance of African trypanosomiasis. Report of a WHO expert committee
25. Fluoroquinolone antimicrobial agents